[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rectal-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rectal-adenoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619169","use-of-a-novel-camera-to-check-the-bowel-after-polyp-or-tumour-removal-100619169",false,"NCT07341126","Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal","Surveillance Digital Rectoscopy After Local Excision of Rectal Tumours","R-ALERT","Inclusion Criteria:\n\nAll participants who are capable of giving informed consent. All participants aged 16 years or over. All patients must have had a rectal tumour\u002F polyp removed within easy reach of the rigid sigmoidoscope.\n\nAll participants must be resident in the United Kingdom.\n\nExclusion Criteria:\n\nUnable to give informed consent. Under the age of 16 years","ALL","16 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy). Afterwards, it is important to check the area with regular camera tests. If checks are delayed, re-growths could be serious and may be untreatable. COVID and other factors have led to long waiting lists for camera checks and in NHS Lothian around 20% of all camera checks are done more than 6 months late.\n\nThe investigators want to try a new camera and approach that would allow us to reduce waiting lists. Using a short camera called a 'rectoscope' to check the lower bowel has already been shown to be safe, comfortable and acceptable to patients with other conditions. In fact, patients are unlikely to feel or realise any difference between the rectoscope and standard camera tests.\n\nThe investigators want to show that this 'rectoscope' can be safely used in the outpatient clinic with an enema (suppository) instead of strong bowel medicine taken by mouth the day before. This would mean the camera checks happen on time and would reduce waiting lists for other important tests.\n\nThe investigators will include 30 patients across three stages of our study. In the first set of patients, the investigators will use the rectoscope alongside the usual endoscope in the endoscopy room using the usual oral bowel medicine. This stage will check the rectoscope is acceptable to the patient and the doctor. In the next 10 patients the investigators will use a suppository instead of oral bowel medicine still using both cameras. Finally, the investigators will use the rectoscope in the outpatient clinic with an suppository to show this is an easy, effective and acceptable way to deliver timely camera checks.",[25,26,27,28,29],"Bowel Cancer","Polyp Rectal","Rectal Cancer","Rectal Adenocarcinoma","Rectal Adenoma",[31,32],"LumenEye","Rectoscopy","NOT_YET_RECRUITING","2026-05-28",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2027-05-01",{"name":43,"class":44},"University of Edinburgh","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100526334","paradigm---en-bloc-trial-with-the-endoquest-endoluminal-surgical-els-system-100526334","NCT06133387","PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM Study: Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM","Preoperative Inclusion Criteria:\n\n1. Subject is ≥22 years at the time of consent.\n2. Subject has a BMI ≤ 50 kg\u002Fm2.\n3. Subject has an ASA score of ≤ 3.\n4. Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n5. Subject has lesion ≤ 7 cm in size (dimension of greatest extent) and ≤ 75% of the colorectal circumference as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n6. Subject is eligible for standard endoscopic submucosal dissection.\n7. Subject agrees to participate in the study by giving signed informed consent.\n\nPreoperative Exclusion Criteria:\n\n1. Subject anatomy is unsuitable for endoscopic visualization or endoluminal surgery.\n2. Subject has active left-sided inflammatory bowel disease.\n3. Subject has an untreated active infection at the time of the procedure.\n4. Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled).\n5. Subject has a severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions (e.g., cancer).\n6. Subject is breastfeeding or pregnant or intends to become pregnant during the study.\n7. Subject is currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n8. Subject with EF ≤ 45, high cardiac or high pulmonary risk (these subjects require clearance from a cardiologist and pulmonologist, as applicable).\n9. Subject on preoperative blood thinners, such as coumadin or heparin, that cannot be weaned prior to surgery.\n10. Subject is moderately or severely immunocompromised.\n11. In the opinion of the Investigator, the subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.\n\nIntraoperative Exclusion Criteria (assessed with third-party endoscope):\n\n1. Inadequate bowel prep.\n2. Complex anatomical findings not feasible for an endoluminal approach.\n3. Anatomical narrowing distal to the lesion site.\n4. Lesion not located in the rectum or sigmoid colon.\n5. Lesion size \\>7 cm (dimension of greatest extent) or occupies \\>75% of the colorectal circumference.\n6. Lesion demonstrates characteristics indicative of invasive carcinoma, such as failure to lift upon submucosal injection, or any other features that raise the Investigator's suspicion of cancer.\n\n   Intraoperative Exclusion Criteria (assessed with study device):\n7. In the opinion of the Investigator, the subject and\u002For subject anatomy is not suitable for study device use for any reason.\n8. Lesion location not accessible by the study device.","22 Years",{"count":56,"type":21},56,"INTERVENTIONAL",[59],"NA","The objective of this study is to evaluate the safety and effectiveness of the Endoluminal Surgical (ELS) System in subjects undergoing specified transanal endoluminal procedures in the rectum and sigmoid colon. Subjects will undergo endoscopic submucosal dissection (ESD), with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.\n\nThe safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge and Days 7 and 30.",[62,63,64,65,29,66,67,68],"Colorectal Lesion","Colorectal Adenoma","Colorectal Polyp","Rectal Lesion","Rectal Polyp","Sigmoid; Lesion","Sigmoid Colon Polyp",[65,70],"Sigmoid Lesion","RECRUITING","2026-04-09",{"date":74,"type":37},"2026-04-14",{"date":76,"type":37},"2025-05-13",{"date":78,"type":21},"2026-06",{"name":80,"class":81},"EndoQuest Robotics, Inc.","INDUSTRY",6,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100624525","advanced-endoscopic-resections-for-rectal-neoplasms-100624525","NCT07410767","Advanced Endoscopic Resections for Rectal Neoplasms","Adoption of Advanced Endoscopic Resection Methods in the Treatment of Rectal Neoplasms","Inclusion Criteria:\n\n* Patients with rectal neoplasms treated by advanced endoscopic resection\n\nExclusion Criteria:\n\n* hybrid resection performed\n* full-thickness resection performed\n* essential procedural or outcome data were unavailable","18 Years",{"count":92,"type":21},300,"This study evaluates how advanced endoscopic resection techniques affect treatment outcomes in adults with rectal cancer.\n\nRectal cancer has traditionally been treated with standard abdominal surgery. Newer endoscopic techniques allow removal of selected early tumors and may reduce treatment-related complications. However, their effectiveness and safety in tumors with deeper invasion are not yet fully established.\n\nThis multicenter retrospective observational study uses existing medical records from adults who underwent endoscopic or surgical resection of rectal tumors between 2015 and 2025. Researchers will analyze anonymized information on procedures performed and treatment outcomes to assess the safety and effectiveness of advanced endoscopic approaches.\n\nThe results of this study may help guide treatment selection and improve care for people with rectal cancer.",[27,28,29,95,96],"Rectal Neuroendocrine Neoplasm","Recurrent Rectal Adenocarcinoma","2026-02-13",{"date":99,"type":37},"2026-02-18",{"date":101,"type":21},"2026-03-01",{"date":103,"type":21},"2026-04-30",{"name":105,"class":44},"Jagiellonian University"]